HELPCybin D/B/A Helus Pharma
What is the market doing?
No clear lean: rangebound and moderately shorted.
Choppy, but holding above its 200-day average. Price is +34% vs its 200-day average.
Moderately shorted, settled Sep 30, 2026, a few days of normal trading to cover.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How HELP is trading
Cybin D/B/A Helus Pharma is +76% over the past year while the S&P 500 is +16%: 60 points ahead of the market.
1-year return · S&P 500 +16%
- vs 200-day average
- +34%
vs 200-day average · a clear uptrend
- RSI (14)
- 40
RSI (14) · neutral
- Below its 52-week high
- 27%
Below its 52-week high
Details›
- Last close2026-10-23
- $10.21
- 1 monthS&P 500 −0.94%
- −19%
- 1 yearS&P 500 +16%
- +76%
- 5 yearsS&P 500 +86%
- −86%
- vs 50-day average$12.09
- −16%
- 52-week high
- $14.03
- 52-week low
- $3.87
- Annualised volatility
- 80%
| Year | Return |
|---|---|
| 2026 (year to date) | +25% |
| 2025 | −7.3% |
| 2024 | −43% |
| 2023 | +38% |
| 2022 | −75% |
| 2021 | −19% |
| 2020 | +13% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 7 | 3 of 7 | +2.1% |
| Feb | 7 | 2 of 7 | −2.7% |
| Mar | 7 | 1 of 7 | −24% |
| Apr | 7 | 4 of 7 | +5.4% |
| May | 7 | 3 of 7 | +3.8% |
| Jun | 7 | 4 of 7 | +13% |
| Jul | 7 | 5 of 7 | +11% |
| Aug | 7 | 2 of 7 | +14% |
| Sep | 7 | 2 of 7 | −4.7% |
| Oct | 8 | 3 of 8 | +2.5% |
| Nov | 7 | 2 of 7 | −7.2% |
| Dec | 7 | 2 of 7 | +13% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.